HC Wainwright Issues Optimistic Outlook for RYTM Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – HC Wainwright increased their Q1 2025 earnings per share estimates for Rhythm Pharmaceuticals in a report released on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($2.79) EPS.

A number of other analysts have also issued reports on RYTM. TD Cowen lifted their target price on Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Jefferies Financial Group assumed coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a “buy” rating and a $80.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $69.08.

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock opened at $52.97 on Thursday. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of -12.23 and a beta of 2.30. The firm’s fifty day moving average price is $56.79 and its 200 day moving average price is $54.48.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). The firm had revenue of $41.83 million for the quarter, compared to analysts’ expectations of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%.

Insider Activity at Rhythm Pharmaceuticals

In related news, CAO Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the sale, the chief accounting officer now directly owns 2,070 shares in the company, valued at $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David P. Meeker sold 4,278 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $254,241.54. Following the completion of the sale, the chief executive officer now directly owns 189,927 shares of the company’s stock, valued at $11,287,361.61. The trade was a 2.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,787 shares of company stock worth $1,901,443 in the last ninety days. 5.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Loomis Sayles & Co. L P bought a new position in Rhythm Pharmaceuticals during the third quarter valued at about $33,353,000. Janus Henderson Group PLC lifted its stake in Rhythm Pharmaceuticals by 103.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company’s stock valued at $68,309,000 after purchasing an additional 621,432 shares during the last quarter. Marshall Wace LLP boosted its holdings in Rhythm Pharmaceuticals by 70.4% during the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company’s stock worth $38,783,000 after buying an additional 286,188 shares in the last quarter. Norges Bank acquired a new position in Rhythm Pharmaceuticals in the fourth quarter worth approximately $11,512,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Rhythm Pharmaceuticals by 224.3% in the fourth quarter. JPMorgan Chase & Co. now owns 264,585 shares of the company’s stock valued at $14,811,000 after buying an additional 182,993 shares in the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.